로딩 중…
지수 로딩 중…
제테마
216080· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,630-1.70%
2026-06-19
Price Chart
제테마-28.22%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 172.64B KRW |
| Revenue | 77.07B KRW |
| Net Income | 3.54B KRW |
| Total Assets | 212.23B KRW |
| Net Assets | 71.76B KRW |
| Employees | 243 |
| Value | |
| P/E | 48.76x |
| P/B | 2.41x |
| P/S | 2.24x |
| EV/EBITDA | 434.07x |
| FCF Yield | 3.12% |
| Profitability | |
| ROE | 4.93% |
| ROA | 1.67% |
| Op. Margin | 0.84% |
| Revenue Growth | 1.08% |
| Earnings Growth | -35.68% |
| Financial Health | |
| Debt Ratio | 295.74% |
| Total Debt | 115.42B KRW |
| FCF | 5.39B KRW |
| Cash | 5.49B KRW |
| Current Ratio | 0.43x |
| Performance | |
| 1Y Return | -28.22% |
| 1M Return | -15.05% |
| From 52W High | -58.95% |
| 1Y MDD | -57.48% |
| Trading | |
| Volume | 209,616 shares |
| Foreign Own. | 3.65% |
| Per Share | |
| EPS | -141 KRW |
| BPS | 1,947 KRW |
Company Info
Jetema originated in 2009 as a bio research company focused on chitosan-applied DDS development. Through a 2014 merger and the 2015 completion of a filler-exclusive factory, the company entered the medical aesthetic market, successfully venturing into the toxin market in 2024. Jetema actively researches and develops hyaluronic acid fillers, botulinum toxin-based pharmaceuticals, sutures, and lifting threads. The company is expanding its global presence, securing license-out agreements with Brazil (2020) and China (2022), and pursuing export contracts with Thailand and market entry into the US in 2024. Jetema is headquartered in Wonju City, Gangwon-do.